Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to the Spero Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.
Spero Therapeutics Inc. (SPRO)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Anson Investments Amin Nathoo And Moez Kassam | 3,750,450 | $5,025,603 | 0.5% | |
| 2. | Renaissance Technologies Jim Simons | 974,653 | $1,306,035 | -1% | 0% |
| 3. | ADAR1 Capital Management Daniel Schneeberger | 743,459 | $996,235 | -20% | 0.16% |
| 4. | DAFNA Capital Management Nathan Fischel | 125,000 | $167,500 | 0.03% | |
| 5. | Citadel Investment Group Ken Griffin | 81,425 | $109,109 | -74% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.24 | 39,727 | Large Shareholder | 5,321,231 | 2022-04-26 | Filing | |
| $8.79 | 16,885 | Large Shareholder | 5,281,504 | 2022-03-30 | Filing | |
| $8.79 | 33,115 | Large Shareholder | 5,264,619 | 2022-03-30 | Filing | |
| $7.63 | 8,006 | Large Shareholder | 5,231,504 | 2022-03-14 | Filing | |
| $7.63 | 15,702 | Large Shareholder | 5,223,498 | 2022-03-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.30 | 17,245 | 379,270 | 2024-11-08 | Filing | ||
| $1.31 | 23,351 | 396,515 | 2024-11-07 | Filing | ||
| $1.35 | 5,912 | 759,085 | 2024-08-27 | Filing | ||
| $1.35 | 2,213 | 531,837 | 2024-08-27 | Filing | ||
| $1.35 | 2,757 | 1,140,809 | 2024-08-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 468,902 | $123,386,872 | 7.61% | |
| 2. | 1,643,757 | $2,416,323 | 0% | |
| 3. | 1,013,438 | $1,489,754 | 0.17% | |
| 4. | 889,979 | $1,308,269 | 0.06% | |
| 5. | 862,700 | $1,268,169 | 0.22% |
News See All
14 Cheap Penny Stocks to Buy According to Analysts
In this article, we will take a detailed look at the 14 Cheap Penny Stocks to Buy According to Analysts. For a quick overview of such stocks, read our article 5 Cheap Penny Stocks to Buy According...
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript
Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.96, expectations were $-0.1.
15 Cash-Rich Penny Stocks Hedge Funds Are Buying
In this article, we will take a detailed look at the 15 Cash-Rich Penny Stocks Hedge Funds Are Buying. For a quick overview of such stocks, read our article 5 Cash-Rich Penny Stocks Hedge Funds Are...
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript
Ted Jenkins: Thank you, operator, and thank you all for participating in today's conference call.
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Spero Therapeutics Second Quarter 2023 Financial Results Conference Call.
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Spero Therapeutics First Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode.
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to Spero Therapeutics Fourth Quarter and Year-End 2022 Financial Results Conference Call. .
Top 10 Losers on Tuesday
The S&P 500 index rose for the second consecutive day, powered by increases in economically sensitive stocks such as commodity producers.
Is SPRO A Good Stock To Buy Now?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database.